Next Article in Journal
Exploration of Artificial Intelligence Use with ARIES in Multiple Myeloma Research
Next Article in Special Issue
Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab
Previous Article in Journal
High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment
Open AccessReview

Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers

Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2019, 8(7), 998; https://doi.org/10.3390/jcm8070998
Received: 27 May 2019 / Revised: 28 June 2019 / Accepted: 5 July 2019 / Published: 9 July 2019
(This article belongs to the Special Issue Liquid Biopsies in Lung Cancer)
The use of targeted agents and immunotherapy for the treatment of advanced non-small-cell lung cancer (NSCLC) has made it mandatory to characterize tumor tissue for patient selection. Moreover, the development of agents that are active against specific resistance mechanisms arising during treatment make it equally important to characterize the tumor tissue at progression by performing tissue re-biopsy. Given that tumor tissue is not always available for molecular characterization due to the paucity of diagnostic specimens or problems relating to the carrying out of invasive procedures, the use of liquid biopsy represents a valid approach to overcoming these difficulties. The most common material used for liquid biopsy in this setting is plasma-derived cell free DNA (cfDNA), which originates from cells undergoing apoptosis or necrosis. However, other sources of tumor material can be considered, such as extracellular vesicle (EV)-derived nucleic acids, which are actively secreted from living cells and closely correspond to tumor dynamics. In this review, we discuss the role of liquid biopsy in the therapeutic management of NSCLC with particular regard to targeted therapy and immunotherapy, and analyze the pros and cons of the different types of samples used in this context. View Full-Text
Keywords: liquid biopsy; diagnostic biomarkers; targeted therapy; acquired resistance; lung cancer liquid biopsy; diagnostic biomarkers; targeted therapy; acquired resistance; lung cancer
Show Figures

Figure 1

MDPI and ACS Style

Pasini, L.; Ulivi, P. Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers. J. Clin. Med. 2019, 8, 998. https://doi.org/10.3390/jcm8070998

AMA Style

Pasini L, Ulivi P. Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers. Journal of Clinical Medicine. 2019; 8(7):998. https://doi.org/10.3390/jcm8070998

Chicago/Turabian Style

Pasini, Luigi; Ulivi, Paola. 2019. "Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers" J. Clin. Med. 8, no. 7: 998. https://doi.org/10.3390/jcm8070998

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop